Forty Pharmaceutical Speakers Announced for the Pharma CI Conference in New Jersey

2008 Pharma CI ConferenceAn unprecedented 40 senior level pharma speakers to headline the 2008 Pharma Competitive Intelligence (CI) Conference on Sept. 15-17 in New Jersey. This is one of the best and largest gathering of pharma CI/BI professionals. The Pharma CI Conference is widely attended by a large variety of executives from large, medium-sized, and smaller pharmaceutical and biotechnology companies.

A sampling of the 40 pharma speakers include the following:

  • Monika Giese, Head Global CI, Novartis Pharma AG
  • Christian Hein, Business Intelligence / Market Research Manager, Actelion Pharmaceuticals Ltd
  • Jerry Hoffman, Manager-Global Competitive Intelligence Strategy, Eli Lilly & Co.
  • Susanne Laningham, Director Business Analysis & Information, Amgen
  • Daniel Pascheles, Vice President, Global Competitive Intelligence, Merck
  • Renee Pierson, Global Intelligence Leader, Johnson & Johnson Pharmaceutical Services
  • Chandra Ramanathan, Director, Global Business and Competitive Intelligence, Bristol-Myers Squibb
  • More speakers and more information can be found at www.pharmaciconference.com

Pharma CI Conference Summary by the Numbers:
40 + pharma leaders to share their expertise with you
20 + hours of learning opportunities
15 + hours of networking time
1 must attend event

Highlights:

  • All pharmaceutical company speakers
  • Ratio of industry attendees vs. vendor attendees is 4:1
  • Unparalleled networking: All the "who's who" of the industry attends
  • Numerous interactive sessions
  • Tailored content with dual tracks

Pharma CI Conference on Sept. 15-17, 2008 in New Jersey

For further information, please visit:
www.pharmaciconference.com

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...